Commit Biologics attending the BioEquity, Milan 2022

April 12 – 2022

Commit Biologics attending the BioEquity, Milan 2022

The BioInnovation Institute supports early-stage life science start-ups that contribute to improving human health for the benefit of people and society. But what are some of the most exciting BII portfolio companies in the biotech space right now? BioInnovation Institute asked their Portfolio Manager, Giles Dudley, and Business Developer, Matthias Wulf. They highlighted six companies including Commit Biologics.

More news

See all news

October 18 – 2021

Commit Biologics gets accepted into the Venture Lab program at the BioInnovation Institute

Funding Research

We took a chat with the BioInnovation Institute about our mission and vision, key drivers for Commit Biologics and the transition from an academic mindset to a more commercial mindset. Read more at BioInnovation …

August 28 – 2023

Commit Biologics appoints Krishna Polu as Chief Executive Officer

Employees News

Krishna Polu is appointed CEO of Commit Biologics. Krishna brings a wealth of operating experience to the team with a track record of pipeline advancement and drug approvals across multiple therapeutics areas. Most recently, …

January 28 – 2025

Commit Biologics announces €5.5m seed financing extension investment by Korys to further develop its Bispecific Complement Engaging (BiCE™) platform

Funding News

Additional funding from new investor Korys, joining existing syndicate members Novo Holdings and Bioqube Ventures, brings total seed financing to €21.5m Funds will be used to further develop Commit’s BiCE platform and move towards …

For inquiries please contact us
at info@commitbio.com

Commit Biologics ApS
Universitetsbyen 83
8000 Aarhus C, Denmark

info@commitbio.com
LinkedIn